Choosing a Market Entry Path: Hong Kong and Turkey Medical Device Registration Compared

Hong Kong and Turkey both require careful medical device regulatory planning, but they operate with different practical priorities.

Hong Kong is best understood as a documentation and responsibility-based listing system under the Medical Device Administrative Control System, or MDACS. The central questions are whether the device is correctly classified, whether the manufacturer and Local Responsible Person can support the application, whether the technical file is complete, and whether post-market obligations can be maintained after listing.

Turkey is more strongly shaped by its Product Tracking System, known as ÜTS. The recent TCKKD-KLVZ-03 guideline gives companies a clearer framework for company registration, document registration, MDR and IVDR product registration, imported product data changes and transitional process applications. Its most practical change is that physical submission is no longer required for certain document registration and update applications, provided the relevant files are uploaded correctly to the system.

For international manufacturers, the distinction is important. Hong Kong preparation should start with classification, local representation and technical evidence. Turkey preparation should start with ÜTS readiness, document legalization, Turkish translation and data consistency.

Hong Kong: A Closer Look at MDACS

Hong Kong's Medical Device Division under the Department of Health administers MDACS. The system is administrative in nature, but in practice it has become important for market credibility, institutional purchasing and regulatory risk management.

Although Hong Kong has historically used a voluntary listing framework for many medical devices, companies should not treat it as optional from a commercial perspective. Hospitals, distributors, procurement teams and healthcare buyers may expect evidence that a device has been properly assessed, listed or supported by appropriate compliance documentation.

For manufacturers seeking market access, MDACS helps demonstrate that the product has been reviewed against Hong Kong's expectations for safety, performance, quality management and post-market control.

Device Classification in Hong Kong

Classification is one of the first and most important steps. Hong Kong uses a risk-based approach for general medical devices.

The common categories are:

• Class I for low-risk devices
• Class II for medium-risk devices
• Class III for high-risk devices
• Class IV for highest-risk devices

This classification affects the amount and depth of evidence required. A simple low-risk product may need a more straightforward file, while an implantable, life-supporting or high-risk device may require stronger clinical evidence, risk management documentation and quality system support.

Companies should assess classification based on the intended use, duration of contact, invasiveness, whether the device delivers energy or medicine, whether it supports or sustains life, and the potential consequence of failure.

A common mistake is to assume that classification in the EU, United States or another jurisdiction will automatically map to Hong Kong. Overseas classification can be useful supporting context, but the Hong Kong submission should still include a clear classification rationale that matches the product's intended use and presentation in the Hong Kong market.

The Role of the Local Responsible Person in Hong Kong

For foreign manufacturers, appointing a Local Responsible Person, or LRP, is one of the most important operational requirements.

The LRP should be a Hong Kong registered entity with valid business registration. More importantly, the LRP acts as the local regulatory anchor for the product. This role can include maintaining documentation, communicating with the Medical Device Division, supporting applications, coordinating adverse event reporting and helping manage field safety corrective actions.

The LRP is especially important because the manufacturer may not have a physical presence in Hong Kong. Without a reliable LRP, even a strong technical file can become difficult to manage after listing.

A capable LRP should understand:

• The device and its intended use
• The manufacturer and supply chain
• The submitted technical documentation
• Local distribution arrangements
• Complaint handling and vigilance procedures
• Change management obligations
• Recall and field safety processes

This makes LRP selection more than an administrative appointment. It is a long-term compliance decision.

Hong Kong Technical Documentation

Hong Kong medical device registration relies heavily on a clear and consistent technical documentation package.

A typical submission may include:

• Device description and specifications
• Intended use and indications
• Classification rationale
• Manufacturing site information
• Quality management system certification, commonly ISO 13485
• Summary Technical Documentation where applicable
• Risk analysis and risk management records
• Clinical evaluation or performance evidence
• Test reports and standards compliance evidence
• Labels, packaging and instructions for use
• Declaration or certification documents
• Post-market surveillance arrangements
• Adverse event and recall procedures

The strongest submissions are not merely large files. They are coherent files. The device name, model number, manufacturer, certificate scope, intended use and labelling should match across the entire document set.

If a certificate covers only certain product families, the application should not imply a broader scope. If the intended use in the label differs from the clinical evaluation or declaration documents, the application may attract questions. If the model numbers on test reports do not match the commercial product, the applicant should prepare a clear bridge or justification.

Quality Management System Expectations in Hong Kong

A quality management system is central to Hong Kong medical device compliance. ISO 13485 is commonly used because it is internationally recognized and directly relevant to medical device manufacturing.

The QMS evidence should support the manufacturer's ability to consistently produce safe and effective devices. It should also support complaint handling, corrective and preventive action, supplier control, production control, document control and post-market monitoring.

For higher-risk devices, weak QMS evidence can undermine the entire application. Even when the product has strong test data, regulators and purchasers will still want confidence that the device can be manufactured consistently and monitored after distribution.

Labelling and Instructions for Use in Hong Kong

Labelling is a practical area where many applications need careful review. Hong Kong market documents should support safe use by local users and healthcare professionals.

Important points include:

• Product name and model consistency
• Manufacturer details
• LRP or local contact details where applicable
• Intended use
• Warnings and precautions
• Contraindications
• Storage conditions
• Sterility status where relevant
• Instructions for safe operation
• Traceability information such as lot or serial number

For devices used by patients or non-specialist users, instructions should be especially clear. If bilingual labelling or additional local labelling expectations apply, the applicant should plan this early because labelling changes can affect packaging, import preparation and distributor readiness.

Importers, Distributors and Local Market Control in Hong Kong

Hong Kong market entry is not only about the manufacturer. Importers and distributors also affect compliance because they handle product movement, storage, traceability and customer-facing communication.

Companies should confirm that local partners can maintain proper records and support field action if needed. This is especially important for devices distributed through multiple channels.

Local partners should be able to identify where products were supplied, respond to complaints, escalate safety issues, and coordinate with the LRP and manufacturer when corrective action is required.

Hong Kong Post-Market Obligations

Post-market control is a major part of Hong Kong medical device compliance. Listing is not the end of the regulatory process.

Companies should maintain systems for:

• Complaint handling
• Adverse event review
• Adverse event reporting where required
• Field safety corrective actions
• Recall planning
• Product change assessment
• Documentation updates
• Distributor and importer communication
• Periodic compliance review

For high-risk devices, post-market obligations should be planned before launch. A company should know who receives complaints, who assesses reportability, who communicates with the authority, who notifies customers, and who maintains records.

Change management is also important. Changes to design, manufacturing process, intended use, labelling, certificate scope or critical suppliers may require review and possible notification. Companies should not assume that a listed device can be changed freely after approval or listing.

Turkey: ÜTS and the TCKKD-KLVZ-03 Direction

Turkey's system is more centralized around ÜTS, the Product Tracking System. The TCKKD-KLVZ-03 guideline clarifies how companies should manage company registration, document notification, product registration, MDR and IVDR applications, imported product data changes and transitional process applications.

The key practical development is the removal of physical submission for certain document registration and update applications. If the original document and, where applicable, the Turkish document are uploaded to the correct fields in ÜTS, physical submission to the Turkish Medicines and Medical Devices Agency may no longer be necessary for those applications.

This can reduce delays caused by international courier delivery, original document arrival, physical file preparation, agency submission and document return.

However, this does not reduce the importance of the document itself. It increases the importance of uploading the correct, complete, legible and verifiable document from the beginning.

For more details about medical device registration in Turkey, refer to https://www.medikozceviri.com/.

Turkey Documentation and Translation Considerations

Turkey's process places strong practical emphasis on document formalities and Turkish-language documentation.

Companies may need to manage:

• Company registration in ÜTS
• Document registration
• Product registration
• MDR or IVDR product information
• Imported product data changes
• Transitional process applications
• Apostille or e-apostille verification
• Consular approval where applicable
• Sworn Turkish translations
• Manufacturer and importer data consistency
• Certificate scope and product scope alignment

The removal of physical submission does not mean apostille, e-apostille, consular approval or sworn translation requirements disappear. If the document is incomplete, incorrectly translated, unverifiable or inconsistent with the product record, the application can still be delayed.

For MDR products, particular attention should be paid to product class, classification rule, Basic UDI-DI, EU certificate scope, EU Declaration of Conformity, intended use, labelling and instructions for use. For IVDR products, risk class, testing purpose, place of use and conformity assessment route may also be critical.

Hong Kong and Turkey Compared

Hong Kong and Turkey both require consistency between product information and supporting documentation, but the risk points differ.

In Hong Kong, the main risk is often an incomplete regulatory story. The product classification, intended use, technical evidence, QMS certificate, label and post-market arrangements must work together. The LRP must also be able to support the device after listing.

In Turkey, the main risk is often a system and document mismatch. The ÜTS record, certificate, declaration, apostille, Turkish translation, manufacturer details, importer details, product code and intended use must align precisely.

Hong Kong is more focused on local accountability and lifecycle compliance. Turkey is more focused on system-based registration, document verification and formal consistency.

Practical Strategy for Manufacturers

For Hong Kong, manufacturers should begin with a regulatory gap assessment. The company should confirm the device class, identify the correct listing route, appoint or confirm the LRP, review technical documentation, check ISO 13485 evidence, prepare labelling and establish post-market procedures.

For Turkey, manufacturers and importers should prepare the ÜTS process by checking whether documents require apostille, e-apostille or consular approval, preparing sworn Turkish translations, confirming certificate scope, and ensuring that all product identifiers are consistent.

The practical lesson is that both systems reward preparation. Hong Kong rewards a complete and well-supported technical and post-market file. Turkey rewards accurate digital submission, verified documents and careful translation.

Conclusion

Hong Kong should be treated as a serious regulatory market, especially for companies selling to hospitals, healthcare institutions or professional users. Even where the framework is administrative, the practical expectations around classification, LRP responsibility, technical documentation, QMS evidence and post-market surveillance are substantial.

Turkey's latest TCKKD-KLVZ-03 direction makes parts of the process faster by reducing physical document submission for certain applications. But faster does not mean lighter. The quality of uploaded documents, sworn translations, apostille verification and MDR or IVDR consistency remains central.

For companies entering both markets, the best approach is to prepare a strong master technical file, then adapt it locally. Hong Kong adaptation should focus on MDACS, LRP and post-market readiness. Turkey adaptation should focus on ÜTS, Turkish documentation and document verification.